On July 15, 2022, Zhizhen Biotech announced the completion of a Series B financing of over 100 million yuan, led by Dachen Caizhi, followed by Daoyuan Capital, Huihe Capital, Kaipu Biology, Anbiping, and old shareholder Qiming Venture Capital. This round of financing will be used to accelerate the company’s product market development, new technology and new product development, etc.
As a state-level high-tech enterprise that provides flow fluorescence multi-joint inspection products for clinical diagnosis and life science research, Zhizhen Bio has always adhered to the mission of “innovating to change the world and caring for life and health”. In recent years, it has launched a series of innovative flow fluorescence Products, maintain strong research and development capabilities and product iteration capabilities; in order to ensure product quality and service capabilities, the company continues to invest in human and material resources to build a complete supply chain system and a nationwide customer service system, with nearly 10,000 square meters in Beijing and Wuxi Production and quality assurance center to ensure reliable product quality and sufficient production capacity.
media coverage
Investment World Venture State Investment China Network Dynamic Point Technology Investment China Network Yiou Investment World Venture State TechWeb
Related events
- Zhizhen Bio has raised more than 100 million yuan in Series B financing2022-07-15
- Focusing on hematological testing and diagnosis, “Zhizhen Bio” completed nearly 100 million yuan in Series A financing2020-08-20
This article is reprinted from: https://readhub.cn/topic/8hFe6HWsDZ4
This site is for inclusion only, and the copyright belongs to the original author.